Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.

Progressive neuronal death in brainstem nuclei and widespread accumulation of α-synuclein are neuropathological hallmarks of Parkinson's disease (PD). Reduction of α-synuclein levels is therefore a potential therapy for PD. However, because α-synuclein is essential for neuronal development and function, α-synuclein elimination would dramatically impact brain function. We previously developed conjugated small interfering RNA (siRNA) sequences that selectively target serotonin (5-HT) or norepinephrine (NE) neurons after intranasal administration. Here, we used this strategy to conjugate inhibitory oligonucleotides, siRNA and antisense oligonucleotide (ASO), with the triple monoamine reuptake inhibitor indatraline (IND), to selectively reduce α-synuclein expression in the brainstem monoamine nuclei of mice after intranasal delivery. Following internalization of the conjugated oligonucleotides in monoamine neurons, reduced levels of endogenous α-synuclein mRNA and protein were found in substantia nigra pars compacta (SNc), ventral tegmental area (VTA), dorsal raphe nucleus (DR), and locus coeruleus (LC). α-Synuclein knockdown by ∼20%-40% did not cause monoaminergic neurodegeneration and enhanced forebrain dopamine (DA) and 5-HT release. Conversely, a modest human α-synuclein overexpression in DA neurons markedly reduced striatal DA release. These results indicate that α-synuclein negatively regulates monoamine neurotransmission and set the stage for the testing of non-viral inhibitory oligonucleotides as disease-modifying agents in α-synuclein models of PD.

• Publication year

  2017

• Venue

  Molecular Therapy

• Publication date

  2017-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ymthe.2017.11.015PMID 29273501PMCID PMC5835151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• O 1-7-4-2 Abnormal autophagy / lysosome function may play some role in Parkinson ’ s disease

  2018cited by this paper
• Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder

  2017cited by this paper
• Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates

  2016cited by this paper
• Alpha‐synuclein propagation: New insights from animal models

  2016cited by this paper
• Role of microRNAs in the Regulation of α-Synuclein Expression: A Systematic Review

  2016cited by this paper
• Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration

  2015cited by this paper
• shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.

  2015cited by this paper
• Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies

  2015cited by this paper
• Target Gene Abundance Contributes to the Efficiency of siRNA-Mediated Gene Silencing

  2014cited by this paper
• Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model

  2013cited by this paper
• α-Synuclein Inhibits Intersynaptic Vesicle Mobility and Maintains Recycling-Pool Homeostasis

  2012cited by this paper
• Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease

  2012cited by this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cited by this paper
• Stem-loop RT-qPCR for microRNA expression profiling.

  2012cited by this paper
• Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases.

  2012cited by this paper
• Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway.

  2012cited by this paper
• Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects

  2012cited by this paper
• The many faces of α-synuclein: from structure and toxicity to therapeutic target

  2012cited by this paper
• Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons

  2012cited by this paper
• Conditional Expression of Parkinson's Disease-Related Mutant α-Synuclein in the Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration and Degradation of Transcription Factor Nuclear Receptor Related 1

  2012cited by this paper
• An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.

  2011cited by this paper
• Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α‐synuclein

  2011cited by this paper
• Decreased reuptake of dopamine in the dorsal striatum in the absence of α-synuclein.

  2011cited by this paper
• Rho GTPase regulation of α-synuclein and VMAT2: implications for pathogenesis of Parkinson's disease.

  2011cited by this paper
• Sub-regional differences and mechanisms of the short-term plasticity of dopamine overflow in striatum in mice lacking alpha-synuclein.

  2011cited by this paper
• Functional Alterations to the Nigrostriatal System in Mice Lacking All Three Members of the Synuclein Family

  2011cited by this paper
• Synuclein modulation of monoamine transporters

  2011cited by this paper
• Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.

  2010cited by this paper
• Pathogenic Lysosomal Depletion in Parkinson's Disease

  2010cited by this paper
• Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors.

  2010cited by this paper
• Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.

  2010cited by this paper
• Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

  2010cited by this paper
• α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro

  2010cited by this paper
• Clues to how alpha‐synuclein damages neurons in Parkinson's disease

  2010cited by this paper
• Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice.

  2010cited by this paper
• In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration.

  2010cited by this paper
• Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease

  2010cited by this paper
• Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153

  2010cited by this paper
• Increased Expression of a-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis

  2010cited by this paper
• Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein

  2009cited by this paper
• Propagation of host disease to grafted neurons: accumulating evidence.

  2009cited by this paper
• Repression of α-synuclein expression and toxicity by microRNA-7

  2009cited by this paper
• Brain-derived neurotrophic factor controls dopamine D3 receptor expression: Implications for neurodevelopmental psychiatric disorders

  2009cited by this paper
• Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease

  2009cited by this paper
• Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides

  2008cited by this paper
• In vivo silencing of alpha-synuclein using naked siRNA

  2008cited by this paper
• Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain

  2008cited by this paper
• Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

  2008cited by this paper
• Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: methodology and biological significance.

  2008cited by this paper
• RNA learns from antisense.

  2007cited by this paper
• Competition for RISC binding predicts in vitro potency of siRNA

  2006cited by this paper
• Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi.

  2006cited by this paper
• Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.

  2006cited by this paper
• Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi

  2006cited by this paper
• Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

  2006cited by this paper
• Down-regulation of α-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson’s disease rat model ☆

  2006cited by this paper
• Alpha-synuclein enhances dopamine D2 receptor signaling.

  2006cited by this paper
• α-Synuclein enhances dopamine D2 receptor signaling

  2006cited by this paper
• Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.

  2005cited by this paper
• Involvement of 5-HT1A Receptors in Prefrontal Cortex in the Modulation of Dopaminergic Activity: Role in Atypical Antipsychotic Action

  2005cited by this paper
• Does α‐synuclein modulate dopaminergic synaptic content and tone at the synapse?

  2004cited by this paper
• Pharmacokinetics of Intrathecal Oligodeoxynucleotides

  2004cited by this paper
• Role of alpha-synuclein in presynaptic dopamine recruitment.

  2004cited by this paper
• Role of α-Synuclein in Presynaptic Dopamine Recruitment

  2004cited by this paper
• Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.

  2004cited by this paper
• α-synuclein locus duplication as a cause of familial Parkinson's disease

  2004cited by this paper
• Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ‐synuclein, α‐synuclein and double α/γ‐synuclein null mutant mice

  2004cited by this paper
• Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

  2004cited by this paper
• Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?

  2004cited by this paper
• Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions.

  2004cited by this paper
• In vivo efflux of serotonin in the dorsal raphe nucleus of 5‐HT1A receptor knockout mice

  2003cited by this paper
• α-Synuclein Locus Triplication Causes Parkinson's Disease

  2003cited by this paper
• alpha-Synuclein locus triplication causes Parkinson's disease.

  2003cited by this paper
• Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen

  2003cited by this paper
• The mouse brain in stereotaxic coordinates

  2003cited by this paper
• Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein

  2002cited by this paper
• Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP

  2002cited by this paper
• Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

  2002cited by this paper
• α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome

  2001cited by this paper
• The role of 5‐HT1B receptors in the regulation of serotonin cell firing and release in the rat brain

  2001cited by this paper
• Pathoanatomy of Parkinson’s disease

  2000cited by this paper
• Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein.

  2000cited by this paper
• Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein*

  2000cited by this paper
• Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

  2000cited by this paper
• Mice Lacking a-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine

  2000cited by this paper
• Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons

  2000cited by this paper
• Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

  1998cited by this paper
• alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

  1998cited by this paper
• α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

  1998cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• α-Synuclein in Lewy bodies

  1997cited by this paper
• Characterization of a novel protein regulated during the critical period for song learning in the zebra finch.

  1995cited by this paper
• The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system

  1995cited by this paper
• Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine.

  1988cited by this paper
• Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography

  1985cited by this paper

• Comparative analysis of clinically approved lipid nanoparticles for intranasal siRNA delivery against SARS-CoV-2.

  2026cites this paper
• Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain

  2026cites this paper
• Ferroplasticity drives social isolation-induced anxiety via a ventral hippocampal iron-α-synuclein axis.

  2026cites this paper
• Nose-to-brain siRNA delivery by PEI/PPI-based nanoparticles reduces α-synuclein expression in a Parkinson’s disease mouse model

  2025cites this paper
• SNCA-targeted epigenome therapy for Parkinson’s disease alleviates pathological and behavioral perturbations in a mouse model

  2025cites this paper
• Development of a Peptide Inhibitor To Prevent Alpha-Synuclein Fibrillization in Parkinson’s Disease

  2025cites this paper
• RNA-based therapies for neurodegenerative disease: Targeting molecular mechanisms for disease modification.

  2025cites this paper
• Early synaptic changes and reduced brain connectivity in PD-like mice with depressive phenotype

  2025cites this paper
• Advanced gene therapy in Parkinson’s disease through innovations in drug delivery systems

  2025cites this paper
• Alpha-Synuclein Pathophysiology in Neurodegenerative Disorders: A Review Focusing on Molecular Mechanisms and Treatment Advances in Parkinson’s Disease

  2025cites this paper
• Impaired unfolded protein response, BDNF and synuclein markers in postmortem dorsolateral prefrontal cortex and caudate nucleus of patients with depression and Parkinson's disease.

  2025cites this paper
• Dysregulation of serotonergic neurotransmission in Parkinson disease: A key duet.

  2025cites this paper
• Novel Poly-Arginine Peptide R18D Reduces α-Synuclein Aggregation and Uptake of α-Synuclein Seeds in Cortical Neurons

  2025cites this paper
• Nanotechnology in Parkinson’s Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes

  2025cites this paper
• Green-Synthesized Silver Nanoparticles with Nigella sativa: A Multifaceted Approach against Parkinson's Disease in Rats via MicroRNA Modulation.

  2025cites this paper
• Recent Advances in Nose-to-Brain Gene Delivery for Central Nervous System Disorders

  2025cites this paper
• To what extent may aminochrome increase the vulnerability of dopaminergic neurons in the context of Parkinson's disease.

  2024cites this paper
• α‐Synuclein in Parkinson's Disease: From Bench to Bedside

  2024cites this paper
• α-Synuclein pathology as a target in neurodegenerative diseases

  2024cites this paper
• Gene Therapy for Parkinson’s Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance

  2024cites this paper
• Genetic-based diagnostics of Parkinson’s disease and other Parkinsonian syndromes

  2024cites this paper
• Nanotechnology used for siRNA delivery for the treatment of neurodegenerative diseases: Focusing on Alzheimer's disease and Parkinson's disease.

  2024cites this paper
• Tilorone mitigates the propagation of α-synucleinopathy in a midbrain-like organoid model

  2024cites this paper
• Novel Therapeutic Horizons: SNCA Targeting in Parkinson’s Disease

  2024cites this paper
• In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification

  2024cites this paper
• Obtención y caracterización parcial de la proteína humana mutante α-sinucleína G51D y la producción de su anticuerpo policlonal

  2024cites this paper
• Ultrasound-Assisted CRISPRi-Exosome for Epigenetic Modification of α-Synuclein Gene in a Mouse Model of Parkinson's Disease.

  2024cites this paper
• Recent Advances in Clinical Trials in Multiple System Atrophy

  2024cites this paper
• Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases

  2024cites this paper
• Effective lowering of α-synuclein expression by targeting G-quadruplex structures within the SNCA gene

  2024cites this paper
• Recalibrating the Why and Whom of Animal Models in Parkinson Disease: A Clinician’s Perspective

  2024cites this paper
• From Synaptic Physiology to Synaptic Pathology: The Enigma of α-Synuclein

  2024cites this paper
• Modelling human neuronal catecholaminergic pigmentation in rodents recapitulates age-related neurodegenerative deficits

  2024cites this paper
• Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders

  2023cites this paper
• Expression profiles of α-synuclein in cortical lesions of patients with FCD IIb and TSC, and FCD rats

  2023cites this paper
• The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease.

  2023cites this paper
• Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies.

  2023cites this paper
• Antisense therapy: a potential breakthrough in the treatment of neurodegenerative diseases

  2023cites this paper
• Olfactory dysfunction and its related molecular mechanisms in Parkinson’s disease

  2023cites this paper
• The Role of α-Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features

  2023cites this paper
• Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy

  2023cites this paper
• Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.

  2023cites this paper
• Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review

  2023cites this paper
• Advances in Pathogenesis and Treatment of Parkinsons Disease Based on Abnormal Accumulation of Alpha-Synuclein

  2023cites this paper
• Big versus small: The impact of aggregate size in disease

  2023cites this paper
• Parkinson’s disease therapy: what lies ahead?

  2023cites this paper
• Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease.

  2023cites this paper
• Small molecule-based fluorescent probes for the detection of α-Synuclein aggregation states.

  2023cites this paper
• Nucleic acid drug vectors for diagnosis and treatment of brain diseases

  2023cites this paper
• Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research

  2023cites this paper
• Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases

  2022cites this paper
• Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

  2022cites this paper
• Up and Down γ-Synuclein Transcription in Dopamine Neurons Translates into Changes in Dopamine Neurotransmission and Behavioral Performance in Mice

  2022influential citation
• Translational Approaches for Brain Delivery of Biologics via Cerebrospinal Fluid

  2022cites this paper
• Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update

  2022cites this paper
• Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies

  2022cites this paper
• Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disorders

  2022cites this paper
• Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches

  2022cites this paper
• ReviewEmerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A

  2022cites this paper
• Intracerebral administration of a modified antisense oligonucleotide targeting the dopamine system in a mouse model of Parkinson’s disease

  2022cites this paper
• Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders

  2022cites this paper
• Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives

  2022cites this paper
• Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology

  2022cites this paper
• miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease

  2022cites this paper
• Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics.

  2022cites this paper
• CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood–Brain Barrier and Towards Specific Cellular Targeting

  2022cites this paper
• The Hidden Cell-to-Cell Trail of α-Synuclein Aggregates.

  2022cites this paper
• Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models

  2021cites this paper
• Intranasal drug delivery: opportunities and toxicologic challenges during drug development

  2021cites this paper
• Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight

  2021cites this paper
• Viral alpha-synuclein knockdown prevents spreading synucleinopathy

  2021cites this paper
• Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy

  2021influential citation
• A novel multi-target strategy to attenuate the progression of Parkinson's disease by diamine hybrid AGE/ALE inhibitor.

  2021cites this paper
• The AKT modulator A-443654 reduces α-synuclein expression and normalizes ER stress and autophagy

  2021cites this paper
• Understanding the Potential of Genome Editing in Parkinson’s Disease

  2021cites this paper
• Current experimental disease-modifying therapeutics for multiple system atrophy

  2021cites this paper
• Simultaneous quantitation of inorganic ions in oligonucleotides using mixed-mode liquid chromatography coupled with a charged aerosol detector.

  2021cites this paper
• Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies

  2021cites this paper
• Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex

  2021cites this paper
• Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease.

  2021cites this paper
• Genotype-driven therapeutic developments in Parkinson’s disease

  2021cites this paper
• Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice

  2021influential citation
• α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

  2021cites this paper
• A novel treatment for Parkinson's disease and ALS: Combined cell and gene therapies

  2021cites this paper
• Therapeutic antisense oligonucleotides for movement disorders

  2020cites this paper
• Antisense oligonucleotides targeting alpha-synuclein reduce pre-formed fibril-induced Lewy pathology and improve some domains of cognitive and motor performance

  2020influential citation
• Therapeutic innovation in Parkinson’s disease: a 2020 update on disease-modifying approaches

  2020cites this paper
• Effect of cerebrospinal fluid circulation on nose-to-brain direct delivery and distribution of caffeine in rats.

  2020cites this paper
• From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein

  2020cites this paper
• In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons

  2020cites this paper
• Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys

  2020cites this paper
• Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era

  2020cites this paper
• Current Management and Emerging Therapies in Multiple System Atrophy

  2020cites this paper
• α-Synuclein in Parkinson’s Disease: Does a Prion-Like Mechanism of Propagation from Periphery to the Brain Play a Role?

  2020cites this paper
• Recent Strategies for Targeted Brain Drug Delivery.

  2020cites this paper
• Silybin as a potent inhibitor of a-synuclein aggregation and associated cytotoxicity against neuroblastoma cells induced by zinc oxide nanoparticles

  2020cites this paper
• Serotonin-induced miR-221/222 contribute to the activation of hepatic stellate cells

  2020cites this paper
• Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts

  2020cites this paper
• Long non-coding RNAs in immune regulation and their potential as therapeutic targets.

  2020cites this paper
• MSA: From basic mechanisms to experimental therapeutics.

  2020cites this paper